Jump Financial LLC Invests $340,000 in Novo Nordisk A/S $NVO

Jump Financial LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,900 shares of the company's stock, valued at approximately $340,000.

Several other large investors also recently made changes to their positions in NVO. Copeland Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 184.8% during the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after purchasing an additional 255 shares in the last quarter. North Capital Inc. purchased a new stake in Novo Nordisk A/S during the first quarter valued at about $27,000. Park Square Financial Group LLC purchased a new stake in Novo Nordisk A/S during the fourth quarter valued at about $29,000. Stone House Investment Management LLC purchased a new stake in Novo Nordisk A/S during the first quarter valued at about $30,000. Finally, Disciplina Capital Management LLC lifted its stake in Novo Nordisk A/S by 162.3% during the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after buying an additional 297 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 1.0%

NVO stock traded down $0.59 during trading hours on Thursday, hitting $56.15. The company's stock had a trading volume of 8,751,850 shares, compared to its average volume of 11,724,782. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $250.71 billion, a PE ratio of 15.43, a price-to-earnings-growth ratio of 1.96 and a beta of 0.66. Novo Nordisk A/S has a 12 month low of $45.05 and a 12 month high of $138.22. The stock has a 50 day moving average price of $59.96 and a two-hundred day moving average price of $67.96.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were issued a dividend of $0.4119 per share. This represents a yield of 240.0%. The ex-dividend date was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

Analyst Upgrades and Downgrades

NVO has been the subject of a number of analyst reports. HSBC lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price objective for the company. in a research note on Thursday, July 31st. BNP Paribas raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research report on Wednesday, August 13th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 price target for the company in a research report on Wednesday, August 13th. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Finally, Dbs Bank raised shares of Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, August 22nd. Three investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and an average target price of $81.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.